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Abstract
OBJECTIVES: To compare health-related quality of life (QoL) in patients undergoing transcatheter aortic valve implantation via transapi-
cal access (TA TAVI) with patients undergoing surgical aortic valve replacement (SAVR).
METHODS: One hundred and forty-four high-risk patients referred for aortic valve replacement underwent TAVI screening and were
assigned to either TA TAVI (n = 51, age 79.7 ± 9.2 years, logistic EuroSCORE 26.5 ± 16.1%, 51% males) or SAVR (n = 93, age 81.1 ± 5.3
years, logistic EuroSCORE 12.1 ± 9.3%, 42% males) by the interdisciplinary heart team. QoL was assessed using the Short Form 36
(SF-36) Health Survey Questionnaire and the Hospital Anxiety and Depression Scale. Furthermore, current living conditions and the
degree of independence at home were evaluated.
RESULTS: Patients undergoing TA TAVI were at higher risk as assessed by EuroSCORE (26.5 ± 16 vs. 12.1 ± 9, P < 0.001) and STS score
(6.7 ± 4 vs. 4.4 ± 3, P < 0.001) compared with SAVR patients. At the 30-day follow-up, the rate of mortality was similar and amounted to
7.8% for TA TAVI and 7.5% for SAVR patients and raised to 25.5% in TA TAVI and 18.3% in SAVR patients after a follow-up period of 15 ±
10 months. Assessment of QoL revealed no differences in terms of anxiety and depression between TA TAVI and SAVR patients. The SF-
36 mental health metascore was similar in both groups (65.6 ± 19 vs. 68.8 ± 22, P = 0.29), while a signiﬁcant difference was observed in
the physical health metascore (49.7 ± 21 vs. 62.0 ± 21, P = 0.015). After adjustment for baseline characteristics, this difference disap-
peared. However, every added point in the preoperative risk assessment with the STS score decreased the SF-36 physical health dimen-
sion by two raw points at the follow-up assessment.
CONCLUSIONS: Selected high-risk patients undergoing TAVI by using a transapical access achieve similar clinical outcomes and QoL
compared with patients undergoing SAVR. Increased STS scores predict worse QoL outcomes.
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INTRODUCTION
Aortic stenosis is the most frequent degenerative valve disease in
developed countries and its prevalence is linked to prolonged
life expectancy and the ageing of the population [1]. As aortic
stenosis is a chronic disease with a progressive course, the prog-
nosis is dismal when left untreated. Five years after the onset of
symptoms [2, 3], only 20% of patients are alive without adequate
treatment. Surgical aortic valve replacement (SAVR) is the
standard therapy for patients with severe symptomatic aortic
stenosis and is able to improve symptoms, survival [1, 4] and
health-related quality of life (QoL) [5]. However, with age comes
an increase in comorbidities and also an increased risk for SAVR.
Especially for these patients, transcatheter aortic valve implant-
ation (TAVI) has emerged as a less-invasive and valuable treat-
ment alternative.
Since being used in man for the ﬁrst time in 2002 [6], the
technology of TAVI has rapidly improved, and implantation via a
transapical access [7] route has been developed. The transapical
approach represents an attractive alternative and has proved its
safety and efﬁcacy. In addition to the achievement of favourable
clinical results, the improvement of health-related QoL [8] is of
major importance for a patient population at high risk and with
limited life expectancy.
The purpose of the present study was to evaluate
intermediate-term QoL in high-risk patients undergoing either
SAVR or TAVI via transapical access (TA TAVI).
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MATERIALS AND METHODS
Study population
Between November 2007 and June 2010, 144 high-risk patients
with severe symptomatic aortic stenosis were referred to our
centre for evaluation and underwent either TA TAVI or SAVR.
Assignment to either group was performed by the interdiscip-
linary heart team on the basis of the individual’s risk proﬁle
using the EuroSCORE [9] and STS risk calculator [10], the tech-
nical feasibility of either therapy or the patients’ preferences.
Patients undergoing transfemoral TAVI were excluded from this
study focusing on QoL after conventional and catheter-based
surgical therapy for aortic valve replacement.
Baseline evaluation included the assessment of medical
history and a physical examination, the performance of trans-
thoracic and transoesophageal echocardiography, carotid ultra-
sonography, right and left heart catheterization, coronary- and
aortic angiography, and computed tomography with three-
dimensional aortic root reconstruction. The preoperative demo-
graphics are summarized in Table 1.
All patients were informed about the speciﬁc risks of both
treatment modalities and gave written consent for the assigned
procedure as well as for data collection and evaluation. The
study protocol was in accordance with the local ethics commit-
tee guidelines.
Procedure
Transapical aortic valve implantation as well as SAVR techniques
have been described previously [11, 12]. The Edwards Sapien
bioprosthesis is available for implantation with transapical access
in our centre and devices with diameters of 23 and 26-mm were
used in the present study. All implantations were performed
under general anaesthesia via a small left-sided antero-lateral
thoracotomy. Transient epicardial pacemaker electrodes were
used for rapid ventricular pacing at 160–180 beats/min during
balloon valvuloplasty and device delivery. The prosthesis was
placed in the native aortic annulus under ﬂuoroscopic guidance.
Prophylactic antibiotic therapy was administered 1 h before the
procedure. All patients received weight-adapted heparin during
the intervention and dual antiplatelet therapy with 100 mg of
aspirin indeﬁnitely and 75 mg of clopidogrel once a day was
prescribed for the period of 6 months. SAVR was performed in
the customary manner under general anaesthesia using median
sternotomy and extracorporeal circulation under full hepariniza-
tion and myocardial arrest. SAVR patients received the following
bio-prosthetic aortic valves in the present study: Carpentier–
Edwards Magna ease 19 to 25-mm (n = 61), Sorin Mitroﬂow
19 to 25-mm (n = 9), Sutureless ATS Medical Enable 19 to 27-mm
(n = 9), Sorin Solo Stentless 19 to 23-mm (n = 6), Sutureless Sorin
Perceval S 23-mm (n = 6), Stentless ATS Medical 3F 23-mm
(n = 1), or St. Jude Trifecta 23-mm (n = 1).
Revascularization was performed as a concomitant procedure
in 11.8% and as a staged procedure in 25.5% of TA TAVI patients,
whereas concomitant coronary artery bypass grafting was
performed in 47.3% of patients undergoing SAVR. Intervention
as a redo operation was performed in 39.2% of patients with
transapical access and 2.2% of patients with conventional SAVR
(P < 0.001).
QoL assessment
QoL assessment was performed using the Short Form 36 (SF-36)
Health Survey Questionnaire and the hospital anxiety and
depression scale (HADS) after a mean follow-up of 15 ± 10
months. Both questionnaires are validated and established
instruments in assessing the health-related QoL and are routinely
used at our institution, as they are self-explanatory and easy to
complete. In addition, the patients’ current living conditions and
degree of independence at home regarding daily life activities
were evaluated.
Short Form 36
The SF-36 represents the most widely evaluated generic patient
health outcome measure with well-established validity and
reliability [13]. It is a self-administered instrument that takes 
15 min to complete. The questionnaire evaluates the health-
related QoL of the preceding 4 weeks and as a generic measure






Male 26 (51) 39 (41.9) 0.4
Age (years) 79.7 ± 9.2 81.1 ± 5.3 1.0
Body mass index 26.9 ± 6.5 25.9 ± 4.7 0.7
Diabetes 20 (39.2) 22 (23.7) 0.06
Hypertension 47 (92.2) 83 (89.2) 0.8
Dyslipidaemia 43 (84.3) 61 (65.6) 0.02
Logistic EuroSCORE (%) 26.5 ± 16.1 12.1 ± 9.3 <0.001
STSscore (%) 6.7 ± 3.8 4.4 ± 2.6 <0.001
Chronic obstructive pulmonary
disease
13 (25.5) 14 (15.1) 0.2
Peripheral vascular disease 14 (27.5) 7 (7.5) 0.002
Coronary artery disease 38 (74.5) 53 (57) 0.047
Cerebrovascular disease 15 (29.4) 14 (15.1) 0.05
Previous myocardial infarction 14 (27.5) 10 (10.8) 0.02
Previous stroke 3 (5.9) 4 (4.3) 0.9
Glomerular filtration rate
(ml/min, Cockcroft)
50.0 ± 24.6 57.3 ± 23 0.06
Pulmonal arterial pressure
(>60 mmHg)
12 (23.5) 8 (8.6) 0.02
Left ventricular ejection
fraction (%)
49.6 ± 17.2 58.1 ± 10.3 0.006
Aortic valve area (cm2) 0.6 ± 0.2 0.5 ± 0.2 0.1
Aortic mean gradient (mmHg) 45.7 ± 15.3 52.2 ± 14.1 0.008
Sinus rhythm 37 (72.5) 74 (79.6) 0.2
Dyspnoea 0.001
NYHA I 1 (2.0) 6 (6.5)
NYHA II 16 (31.4) 44 (47.3)
NYHA III 28 (54.9) 36 (38.7)
NYHA IV 6 (11.8) 7 (7.5)
Syncope 12 (23.5) 16 (17.2) 0.003
Prior sternotomy/re-operation 20 (39.2) 2 (2.2) <0.001
Prior coronary artery bypass
grafting
18 (35.3) 2 (2.2) <0.001
Prior valve replacement 2 (4) 0 (0) 0.12
Preoperative critical condition 1 (2) 4 (4.3) 0.7
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it does not target any speciﬁc age, disease or treatment group
(www.sf-36.org). The SF-36 has been tested and found suitable
for evaluating health-related QoL also for cardiac surgery [14].
The questionnaire consists of 36 questions covering eight
general health domains: Physical functioning, role-physical,
bodily pain, general health, vitality, social functioning,
role-emotional and mental health. All SF-36 dimensions are
scaled from 0 to 100 points, with increasing scores indicating
higher subjective perception of QoL. Calculating the summaries
of physical as well as mental components results in two meta-
scores (Physical Health and Mental Health) representing the
overall physical and mental state.
Hospital anxiety and depression scale
The HADS (Fig. 1) is a highly accepted, reliable and valid screen-
ing tool in assessing anxiety and depression [15]. It provides a
speciﬁc subscale instrument for the individual assessment of
anxiety (HADS-A) and a subscale for depression (HADS-D).
Fourteen mixed items are divided into speciﬁc questions refer-
ring to HADS-A and speciﬁc items for HADS-D. Every question
needs to be addressed on a four-point scale (0–3) resulting in an
overall score ranging from 0 to 21 points for both the anxiety
and the depression scale. A score in the range of 0–7 is consid-
ered negative, and 8–10 is suggestive of, and ≥11 is indicative of
the probable presence of a mood disorder [16].
Assessment of current living conditions
In conjunction with the SF-36 and HADS questionnaire, three
additional items were assessed:
(i) current living conditions (at home completely independent;
at home self-caring with minor help; at home with assisted
care; in a home for the elderly; in a nursing home);
(ii) autonomy in ﬁlling in the form (alone; with the aid of a
family member; with the aid of a health-care professional);
and
(iii) whether they would undergo the same intervention again.
All questionnaires were answered either in French or German
according to the mother tongue and residence in the French- or
German-speaking part of Switzerland of the patients.
Outstanding returns or incompletely answered questionnaires
were completed by telephone interviews within a 2-month
period by the same specially trained person.
Statistical analysis
Categorical data are expressed as frequency (percentages);
continuous variables are presented as mean ± SD. For the
bivariable analyses, we used χ2-tests for categorical data and the
Mann–Whitney U-test for continuous variables. The bivariable
comparison of the risks for mortality was analysed by means of
the log-rank test. For prediction of the QoL from the type of
treatment, linear regression modelling was used to adjust for sus-
pected confounding factors: logistic EuroSCORE, STS score, pre-
operative dyspnoea and preoperative syncope. We performed
this linear regression analysis separately for the two metascores
of the SF-36, Physical and Mental Health. The same variables
were included into two logistic regression analyses, to predict
the occurrence of anxiety and depression, both measured with
HADS.
All tests used were two-sided, and differences were consid-
ered statistically signiﬁcant for P-values of <0.05. The analyses
were performed using SPSS Statistics 17.0 for Windows.
RESULTS
Study population
Of 144 patients with symptomatic, severe aortic stenosis, 51
patients (79.7 ± 9 years, 26 males) were allocated to TA TAVI and
93 patients (81.1 ± 5 years, 39 males) underwent SAVR.
At baseline TA TAVI patients were more often in NYHA Class
III and IV (66.7 vs. 46.2%, P < 0.001) and had more frequent
syncope (23.5 vs. 17.2%, P < 0.002) compared with SAVR patients.
Furthermore, left ventricular ejection fraction was signiﬁcantly
lower in the TA TAVI group compared with SAVR patients (49.6 ±
17 vs. 58.1 ± 10%, P = 0.006).
In the TA TAVI group, the estimated risk as assessed by the
EuroSCORE (26.5 ± 16 vs. 12.1 ± 9%, P < 0.001) and the STS score
(6.7 ± 4 vs. 4.4 ± 3%, P < 0.001) was signiﬁcantly higher compared
with SAVR-treated patients (Table 1).
Clinical outcomes
Clinical outcome variables are summarized in Table 2. Mortality at
30-day follow-ups were 7.8% for TA TAVI and 7.5% for SAVR
patients. Subsequent follow-ups were performed after 3, 6
months, 1 year and at 15 ± 10 months and provided mortality
rates of 7.8% vs. 7.5%, 15.7% vs. 11.8%, 21.6% vs. 17.2% and 25.5%
vs. 18.3%, respectively, without signiﬁcant differences between the
two groups. Kaplan–Meier survival analysis is illustrated in Fig. 2.
Cerebrovascular events occurred in 5.9% (n = 3) of TA TAVI
patients compared with 5.4% (n = 5) of SAVR patients (P = 0.9).
The rate of myocardial infarction was low in both groups with
3.9% (n = 2) for patients undergoing TA TAVI and none in the
SAVR group (P = 0.12). Permanent pacemaker implantation was
Figure 1: The HADS questions. Seven of the 14 mixed items relate to anxiety
(HADS-A subscale) and seven to depression (HADS-D subscale). Each ques-
tion has a four-point (0–3) response category so that the possible scores
range from 0 to 21 for both anxiety and depression.
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required in 9.8% of patients (n = 5) of TA TAVI patients compared
with 2.2% (n = 2) in the SAVR group (P = 0.1).
Although the need for packed red blood cell transfusions was
signiﬁcantly higher in patients undergoing SAVR (3.9 ± 4 vs. 1.7 ± 3,
P < 0.001), no difference was observed in terms of re-operation
or tamponade, with 3.9% (n = 2) for TA TAVI and 5.4% (n = 5)
for SAVR. TA TAVI patients tended to have a shorter stay at the
intensive care unit (2.5 ± 5 vs. 3.6 ± 9 days) and have a shorter
overall hospital length of stay (14.0 ± 8 vs. 15.3 ± 13 days).
QoL as assessed by SF-36 and HADS
In the TA TAVI group, 70% of patients spontaneously returned
the questionnaires compared with 74% in the surgical group.
Overall clinical follow-up was completed in 99.3% of patients,
and only one patient in the TA TAVI group was lost to follow-up.
The patient ﬂow of the present study including QoL assessment
is presented in Fig. 3.
QoL assessment with the SF-36 questionnaire showed no
signiﬁcant differences in TA TAVI and SAVR patients in the sub-
scales of physical functioning (46.8 ± 27 vs. 61.1 ± 27, P = 0.21),
role-physical (35.5 ± 41 vs. 51.8 ± 40), bodily pain (64.3 ± 27 vs.
71.6 ± 30), vitality (46.6 ± 17.6 vs. 52.5 ± 21), social functioning
(75.4 ± 23 vs. 79.9 ± 22), role-emotional (64.5 ± 44 vs. 67.6 ± 44)
and mental health (75.7 ± 15 vs. 75.0 ± 18) (Fig. 4). In contrast,
the SF-36 subscale for general health (52.4 ± 17 vs. 64.1 ± 17,
P = 0.005) was signiﬁcantly lower in the TA TAVI group, which
was reﬂected in the Metascore Physical Health also showing sig-
niﬁcant lower values in TA TAVI patients when compared with
SAVR patients (50.0 ± 21 vs. 62.0 ± 21, P = 0.015). However, after
adjustment for baseline characteristics in the multivariate model,
this difference disappeared. Mental health improvement after TA
TAVI or SAVR was similar without signiﬁcant differences in this
SF-36 metascore.
Besides these results, anxiety and depression were also equally
distributed between patients undergoing TA TAVI and SAVR. The
anxiety scale of the HADS questionnaire amounted to 4.0 ± 4 for
the transapical TAVI patients vs. 4.0 ± 3 for SAVR patients (P =
1.00), and also the depression scores showed no difference
between the groups (4.7 ± 4 vs. 4.0 ± 4). Comparing patients with
HADS scores indicating anxiety and depression, we observed no
signiﬁcant statistical differences (Fig. 5). Anxiety was present in
5.7% of SAVR and 12.9% of TA TAVI patients (P = 0.25), while de-
pressive disorder was apparent in 17.1% of SAVR and in 12.9% of
TA TAVI patients (P = 0.77).
Risk-score prediction of QoL outcome
In the multivariable regression model, preoperative risk assess-
ment was a predictor for postoperative QoL. Every added point
in the STS score decreased the SF-36 Physical Health dimension
by two raw points at follow-up assessment (P = 0.007).
Reafﬁrming the decision to undergo the same
intervention
Of the patients treated by TA TAVI 87.1% and 94.3% of patients
treated by SAVR reafﬁrmed their decision to undergo the pro-
posed therapy. At the follow-up of 15 ± 10 months 80.6% of TA
TAVI patients compared with 81.4% of SAVR patients reported a
substantial improvement in general health conditions as a result
of the aortic valve intervention.
Need for re-admission to hospital
During the ﬁrst 6 months after TA TAVI 29.0% of patients had to
be re-admitted to hospital care compared with 14.3% of the
patients who underwent SAVR (P = 0.1). All of these patients
required more than one re-admission in the TA TAVI patient
population while 11.4% of SAVR patients required multiple
re-admissions ranging from two to ﬁve times.
Figure 2: Kaplan–Meier survival analysis of the surgical (SAVR) and the transa-
pical TAVI group. The vertical axis represents the probability of survival. The
vertical bar corresponds to the time interval where two-thirds of the patients
are still alive.






30-day mortality 4 (7.8) 7 (7.5) 1.0
Overall hospitalization days 14 ± 8 15.3 ± 12.8 0.9
Days in intermediate care 2.4 ± 4.4 2.1 ± 3.0 0.7
Days in intensive care 2.5 ± 4.6 3.6 ± 9.0 0.8
Concomitant revascularization
(PCI/CABG)
6 (11.8) 44 (47.3) <0.001
Need for pacemaker 5 (9.8) 2 (2.2) 0.1
Stroke 3 (5.9) 5 (5.4) 0.9
Myocardial infarction 2 (3.9) 0 (0) 0.12
Bleeding/tamponade
necessitating re-intervention
2 (3.9) 5 (5.4) 1.0
Intraoperative transfusions of EC 1.7 ± 3.3 3.9 ± 4.0 <0.001
Data are expressed as mean ± SD or n (%). PCI: percutaneous
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Living conditions and degree of independence
At 15 ± 10 months’ follow-up 22.6% of patients treated by TA
TAVI vs. 41.4% of SAVR patients were living independently
without major assistance in daily living activities. Minor assist-
ance was needed in 45.2% after TA TAVI vs. 41.4% after SAVR and
major help (i.e. for personal hygiene, dressing) of family
members or community health services was required in 19.4%
of patients after TA TAVI vs. 10.0% in the SAVR group (P = 0.19).
At the time of follow-up, an overall 9.7% of TA TAVI and 7.1% of
surgically treated patients were living in a geriatric care institu-
tion, while 3.2% of TA TAVI and none of the SAVR patients had
been admitted to a care and nursing home (Fig. 6).
Study-related questionnaires were completed without any as-
sistance in 64.5% of TA TAVI patients and 65.7% in the SAVR
group; 29.0 and 24.3%, respectively, required the help of rela-
tives, and the minority of 6.5 vs. 10.0% were assisted by a health-
care professional (P = 0.78).
DISCUSSION
A respectable number of studies have documented the feasibility
and the advantages of TAVI in the most recent era. TAVI
improves survival compared with medical therapy alone in
patients deemed inoperable [17] and is non-inferior to SAVR in
terms of mortality in selected high-risk patients [18]. These
results might tempt one to extend this seemingly attractive tech-
nology to a larger patient pool [19], particularly with regard to
the patients’ preference for less invasive procedures. But apart
from technical and isolated survival data additional clinical cri-
teria are needed to support further decision making.
Assessment of intermediate-term QoL in patients undergoing
TAVI is scarce and the comparison with SAVR treatment is
missing. Especially in this elderly patient population, the
prolongation of lifetime is one aim of treatment, but this is less
important from a patient’s perspective. When faced with a
limited remaining lifetime, QoL is of major importance to these
elderly patients and preservation or even improvement of QoL is
the primary objective of a therapy approach in a geriatric patient
population.
Considering the baseline characteristics of patients included in
the present study, both groups are characterized by advanced
age and, especially, frailty. Patients in the TA TAVI group were
more affected by comorbidities compared with the surgical
group as reﬂected in the increased logistic EuroSCORE (26.5 ±
16.1 vs. 12.1 ± 9.3) as well as the STS score (6.7 ± 3.8 vs.
4.4 ± 2.6). This is comparable with the estimated risk of patients
included into the PARTNER Trial (Logistic EuroSCORE of 29.3%)
[18] and, furthermore, the preoperative risk presented in the
recent publication on the QoL after TAVI by Georgiadou et al.
[20]. The signiﬁcant difference in preoperative conditions was,
furthermore, expressed in preoperative symptoms, as TA TAVI
patients signiﬁcantly were more often in NYHA Class III and IV
when compared with SAVR patients. At admission 67% of TA
TAVI patients were in NYHA Class III or IV compared with 47% in
the SAVR group (P < 0.05), and 24% of TA TAVI patients experi-
enced preoperative syncope compared with 17.2% in the SAVR
group (P = 0.001). In addition, also left ventricular ejection
fraction (49.6 ± 17 vs. 58.1 ± 10%) accounted unfavourably in the
TA TAVI group.
Despite differences in risk assessment and disease progression,
30-day mortality (7.8 vs. 7.5%), 6-month mortality (15.7 vs.
11.8%) and 1-year mortality (21.6 vs. 17.2%) did not show any
signiﬁcant differences in both groups and complies well with
existing literature data [8, 18, 21].
As demonstrated in this study, TA TAVI patients, although they
were at higher surgical risk, with more advanced aortic valve
Figure 3: Patient flow of the present study.
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disease and a heavier symptom burden, presented outcomes
comparable with the surgical group. The question that needs to
be addressed remains: do TAVI patients have a postoperative
QoL comparable with patients undergoing SAVR?
In contrast to previous reports, we focused in this study on
the comparison of postoperative QoL in patients receiving TA
TAVI and SAVR and used the SF-36 and HADS health-related
questionnaires. According to the SF-36 items of physical func-
tioning, role-physical, bodily pain, vitality, social functioning,
role-emotional and mental health, patients with TA TAVI showed
a similar performance in the QoL as those with SAVR treatment.
A signiﬁcant difference in the subscale general health (Fig. 4),
showing lower values in TA TAVI patients compared with the
SAVR group, might be explained due to the markedly poorer
preoperative condition of the former rather than by the nature
of the performed intervention. In the multivariate regression
model adjusted for confounding factors, we found that the only
preoperative condition to predict a lower QoL outcome was the
STS score. Every one point of the STS score added decreased the
Physical Health Metascore of the SF-36 by two raw points. In
this context, the signiﬁcantly increased STS score in the TA TAVI
group compared with the SAVR group, fully supports the previ-
ous statement.
As emotional well-being might be at least as important as
physical strength and for this reason the HADS, a self-assessment
screening questionnaire designed to simply and yet reliably
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assess and quantify the degree of anxiety and depression, was
used in all patients. No previous TAVI study has evaluated follow-
up outcomes by the HADS so far. The results of this speciﬁc
emotional assessment with the HADS did not show signiﬁcant
differences between TA TAVI and SAVR patients, neither on the
depression nor on the anxiety scale (Fig. 5) at the 15-month
follow-up.
The fact that more than 80% of surviving patients indicated an
improvement in the QoL due to the assigned treatment and
90% reafﬁrmed their decision to undergo the same procedure
again may also add special value on the individual improvement
with regard to the QoL after the procedure.
However, although our study population presented with
advanced age and had multiple comorbid conditions at baseline,
a surprisingly high proportion were able to care for themselves
and live alone with only minor assistance after the intervention
(68% in the transapical TAVI group, 83% in the SAVR group).
After all, two-thirds of the patients could ﬁll in the question-
naires without external help, which indirectly points to the ad-
equate cognitive skills of most of these octogenarians.
Limitations
The present study has several limitations. As with any single-
centre experience, our ﬁndings may not be generalized. The
relatively small sample size, although well within the range of
comparable studies on TAVI, may limit statistical signiﬁcance in
some aspects. All patients in this study were evaluated by an
interdisciplinary heart team and, according to their risk, allo-
cated to either conventional SAVR or TA TAVI. A randomized
comparison would have been preferable in this situation to
create a non-biased statement. The highest risk patients were
assigned to TA TAVI, which might result in a selection bias, and
therefore postoperative QoL values in SAVR and TA TAVI patients
need to be interpreted with caution. There could also be a po-
tential bias due to the relatively high number of patients who
died in either group before assessment of their QoL. QoL is
inﬂuenced by several daily living circumstances and therefore, a
generic tool like the SF-36 reﬂects not just the cardiac causes of
poor QoL. On the other hand, the SF-36 is a validated tool and
this study explicitly addressed the general QoL in this elderly
patient population.
CONCLUSION
This study adds to the growing body of evidence that elderly
patients undergoing transapical TAVI achieve similar clinical out-
comes as well as the health-related QoL compared with patients
undergoing SAVR. This effect was maintained over time and was
still present beyond a year after the intervention. There is a sig-
niﬁcant correlation between the STS score and the QoL. Every
added point in the STS score decreased the SF-36 physical
health dimension by 2 raw points at the follow-up assessment.
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APPENDIX. CONFERENCE DISCUSSION
Dr C. Schlensak (Tübingen, Germany): TAVI was introduced for patients with
aortic stenosis who are not eligible for conventional aortic valve replacement.
Due to the high costs and the potential complications of the TAVI procedure
itself, analysis of the quality of life after TAVI is crucial. Since you could not
identify any differences in quality of life between the groups, transapical TAVI
vs. conventional aortic valve replacement, does this have any impact on the
treatment strategy at your centre?
Dr Huber: I am sorry, what do you mean?
Dr Schlensak: The TAVI patients were the much sicker patients compared to
the conventional aortic replacement patients. However, in comparing the two
groups there was no difference in outcome. Did I understand that correctly?
Dr Huber: Yes, that is correct in terms of quality of life.
Dr Schlensak: Therefore I wonder, does this have any impact on your treat-
ment protocol, whether you treat patients with TAVI or a conventional surgi-
cal procedure?
Dr Huber: Well, there is a patient group where there certainly is an ambi-
guity about selecting the kind of procedure which is best for that patient. We
have that kind of patient, not the patients included in this study now, but
those that are referred for TAVI. But, on the other hand, we have patients that
are beyond 80 years of age, let’s say 83 for example, who might be in quite
good shape but who nevertheless demand transcatheter valve replacement.
And I think in those patients, even more so with the kind of information
coming from the data, I start more and more to agree with doing TAVI in
those patients, even though they might also be candidates for surgery, as
long as they are old enough, because their life expectancy still is limited just
by the nature of their age itself. So I think it would be worth those patients
being included as TAVI patients if they understand what the risks are and
understand the durability issues of the valve, et cetera.
Dr Schlensak: Coming back to the demand of patients, if I understood that
correctly, you have demonstrated (after taking into account the complexity
and comorbidities) that the outcome of both patient groups is the same.
Bearing in mind that the TAVI procedure is very costly and associated with a
higher complication rate, I wonder why not do conventional aortic valve
surgery in these patients?
Dr Huber: Well, this is a fair enough question. In this study there were still
patients that were referred for TAVI evaluation. In those patients we split
apart those that we thought were better suited for surgery and those in
whom we didn’t want to do surgery.
But your ﬁrst question asked whether the patients sent for surgery in this
study would be candidates to go for TAVI next time, and I think I would
answer that question with ‘yes’. In terms of the issues facing the patient, such
as advanced age, three months of sternal healing, etc., I think if we can
shorten the recovery time, and we will certainly do that with TAVI, it is a
beneﬁt we can add to our patients in the older age population, yes.
Dr N. Moat (London, UK): I am trying to work out why you decided to
choose a subgroup of TAVI, that is to say transapical TAVI, to compare with
surgical AVR rather than your whole TAVI population.
Dr Huber: I’m sorry, why we didn’t include transfemorals?
Dr Moat: Why did you choose a subgroup of patients having TAVI, i.e., the
transapical group, rather than the whole population? Was there some reason
for that?
Dr Huber: Well, the bunch of the transapical patient population has been
included. All our transapical patients underwent multidisciplinary screening,
and then we went backwards, and then the quality of life was retrospectively
assessed in all the patients by phone interview. So this information comes
from all the patients.
Dr Moat: A second question. I wouldn’t pretend to be an expert on assessing
quality of life. It is quite a complicated issue and, as I am sure, as you know,
there are very many instruments to assess it. So you could interpret your results
in two ways: one is that there is no difference in quality of life; the other is that
the instruments that you used, the SF-36 and the HADS score, are not very good
instruments in this patient population. Would you like to comment on that?
Dr Huber: Well, the SF-36 is a quite standardized instrument. It has also
been partly used in the PARTNER trials, even though the shorter version, and
it has been validated. It certainly is an instrument that has this validation. You
can use other scores. That will be the subject of another study.
Now, just to get back to your ﬁrst question regarding the number of transa-
pical patients, obviously those patients have to have a long enough follow-up.
So the ones that are more recent were not included in the study. That is why
the number is smaller than the overall number of patients in whom we
would have performed transapical TAVI.
Dr O. Wendler (London, UK): I have one more question, and that is, have
you ever looked in the past into the quality of life of your surgical patients? If
you have done so, would you say that the introduction of TAVI has improved
the outcome in terms of quality of life of the surgical cohort because you
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Dr Huber: From 2001 to 2002, we performed a study in 166 octogenarians
that underwent surgery. Of those, I showed on one of the ﬁrst slides a
glimpse of the aortic valve replacement. But those patients had been investi-
gated before TAVI was introduced at our centre. So I wouldn’t be able to give
you a well-deﬁned answer to that.
Dr Wendler: Well, that was exactly the reason why I was asking, because
you can make a point out of the fact that TAVI, and one would hope so,
would improve the outcomes after conventional surgery, and that would also
include quality of life. So that is maybe a point to look at in the future.
Dr Huber: I would certainly think so, but I don’t have data to support it.
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